Alpha Teknova, Inc. (TKNO)
NGM · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Alpha Teknova, Inc.
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 10.3M | 10.5M | 10.0M | 11.1M |
| Gross Profit | 4.0M | 3.2M | 3.2M | 3.8M |
| Operating Income | -3.4M | -4.0M | -4.6M | -4.3M |
| Net Income | -3.6M | -4.3M | -4.8M | -4.6M |
| Diluted EPS | $-0.07 | $-0.08 | $-0.09 | $-0.08 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 41.4M | 36.7M | 37.7M | 40.5M |
| Gross Profit | 17.5M | 10.3M | 7.2M | 13.4M |
| Operating Income | -28.9M | -31.2M | -26.1M | -17.0M |
| Net Income | -47.5M | -36.8M | -26.7M | -17.3M |
| Diluted EPS | $-1.69 | $-1.16 | $-0.57 | $-0.32 |